34
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Patients with complicated urinary tract infections (cUTIs) frequently receive broad-spectrum antibiotics. We aimed to determine the prevalence and predictive factors of multidrug-resistant gram-negative bacteria in patients with cUTI.

          Methods

          This is a multicenter, retrospective cohort study in south and eastern Europe, Turkey and Israel including consecutive patients with cUTIs hospitalised between January 2013 and December 2014. Multidrug-resistance was defined as non-susceptibility to at least one agent in three or more antimicrobial categories. A mixed-effects logistic regression model was used to determine predictive factors of multidrug-resistant gram-negative bacteria cUTI.

          Results

          From 948 patients and 1074 microbiological isolates, Escherichia coli was the most frequent microorganism (559/1074), showing a 14.5% multidrug-resistance rate. Klebsiella pneumoniae was second (168/1074) and exhibited the highest multidrug-resistance rate (54.2%), followed by Pseudomonas aeruginosa (97/1074) with a 38.1% multidrug-resistance rate. Predictors of multidrug-resistant gram-negative bacteria were male gender (odds ratio [OR], 1.66; 95% confidence interval [CI], 1.20–2.29), acquisition of cUTI in a medical care facility (OR, 2.59; 95%CI, 1.80–3.71), presence of indwelling urinary catheter (OR, 1.44; 95%CI, 0.99–2.10), having had urinary tract infection within the previous year (OR, 1.89; 95%CI, 1.28–2.79) and antibiotic treatment within the previous 30 days (OR, 1.68; 95%CI, 1.13–2.50).

          Conclusions

          The current high rate of multidrug-resistant gram-negative bacteria infections among hospitalised patients with cUTIs in the studied area is alarming. Our predictive model could be useful to avoid inappropriate antibiotic treatment and implement antibiotic stewardship policies that enhance the use of carbapenem-sparing regimens in patients at low risk of multidrug-resistance.

          Electronic supplementary material

          The online version of this article (10.1186/s13756-018-0401-6) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

          Many different definitions for multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) bacteria are being used in the medical literature to characterize the different patterns of resistance found in healthcare-associated, antimicrobial-resistant bacteria. A group of international experts came together through a joint initiative by the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC), to create a standardized international terminology with which to describe acquired resistance profiles in Staphylococcus aureus, Enterococcus spp., Enterobacteriaceae (other than Salmonella and Shigella), Pseudomonas aeruginosa and Acinetobacter spp., all bacteria often responsible for healthcare-associated infections and prone to multidrug resistance. Epidemiologically significant antimicrobial categories were constructed for each bacterium. Lists of antimicrobial categories proposed for antimicrobial susceptibility testing were created using documents and breakpoints from the Clinical Laboratory Standards Institute (CLSI), the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the United States Food and Drug Administration (FDA). MDR was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories, XDR was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two categories) and PDR was defined as non-susceptibility to all agents in all antimicrobial categories. To ensure correct application of these definitions, bacterial isolates should be tested against all or nearly all of the antimicrobial agents within the antimicrobial categories and selective reporting and suppression of results should be avoided. © 2011 European Society of Clinical Microbiology and Infectious Diseases. No claim to original US government works.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Urinary tract infections: epidemiology, mechanisms of infection and treatment options.

              Urinary tract infections (UTIs) are a severe public health problem and are caused by a range of pathogens, but most commonly by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis and Staphylococcus saprophyticus. High recurrence rates and increasing antimicrobial resistance among uropathogens threaten to greatly increase the economic burden of these infections. In this Review, we discuss how basic science studies are elucidating the molecular details of the crosstalk that occurs at the host-pathogen interface, as well as the consequences of these interactions for the pathophysiology of UTIs. We also describe current efforts to translate this knowledge into new clinical treatments for UTIs.
                Bookmark

                Author and article information

                Contributors
                34 932607625 , agomilagrange@gmail.com
                eshawp@gmail.com
                jcarratala@ub.edu
                leibovici@clalit.org.il
                ctebe@idibell.cat
                irith.wiegand@aicuris.com
                laura.vallejotorres@sescs.es
                jmv@icf.uab.cat
                steve.morris@ucl.ac.uk
                elunid_stoddart@hotmail.com
                Sally.Grier@nbt.nhs.uk
                christiane.vank@aicuris.com
                N.Cuperus@umcutrecht.nl
                L.M.C.v.denHeuvel-2@umcutrecht.nl
                noaeliakim@gmail.com
                cuong.vuong@aicuris.com
                Alasdair.Macgowan@nbt.nhs.uk
                ibironke.addy@aicuris.com
                mpujol@bellvitgehospital.cat
                Journal
                Antimicrob Resist Infect Control
                Antimicrob Resist Infect Control
                Antimicrobial Resistance and Infection Control
                BioMed Central (London )
                2047-2994
                14 September 2018
                14 September 2018
                2018
                : 7
                : 111
                Affiliations
                [1 ]ISNI 0000 0000 8836 0780, GRID grid.411129.e, Department of Infectious Diseases, , Hospital Universitari de Bellvitge, Institut Català de la Salut (ICS-HUB), ; Feixa Llarga s/n, L’Hospitalet de Llobregat, 08907 Barcelona, Spain
                [2 ]ISNI 0000 0000 9314 1427, GRID grid.413448.e, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, ; Madrid, Spain
                [3 ]ISNI 0000 0004 0427 2257, GRID grid.418284.3, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), ; Feixa Llarga s/n, L’Hospitalet de Llobregat, 08907 Barcelona, Spain
                [4 ]ISNI 0000 0004 1937 0247, GRID grid.5841.8, University of Barcelona, ; Barcelona, Spain
                [5 ]ISNI 0000 0004 1937 0546, GRID grid.12136.37, Department of Medicine E, Beilinson Hospital, Rabin Medical Center, Petah Tikva; Sackler Faculty of Medicine, , Tel Aviv University, ; Tel Aviv, Israel
                [6 ]AiCuris Anti-infective Cures GmbH, Wuppertal, Germany
                [7 ]ISNI 0000000121901201, GRID grid.83440.3b, UCL Department of Applied Health Research, , University College London, ; London, UK
                [8 ]GRID grid.7080.f, Informatics Unit, Fundació Institut Català de Farmacologia, ; Barcelona, Spain
                [9 ]ISNI 0000 0004 0417 1173, GRID grid.416201.0, Department of Medical Microbiology, , Southmead Hospital, North Bristol NHS Trust, ; Bristol, UK
                [10 ]ISNI 0000000090126352, GRID grid.7692.a, Julius Center for Health Sciences and Primary Care, , University Medical Center Utrecht, ; Utrecht, Netherlands
                Author information
                http://orcid.org/0000-0001-6979-9269
                Article
                401
                10.1186/s13756-018-0401-6
                6137881
                30220999
                187134cb-0e48-4c10-8ddb-91ebd12ecf42
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 24 July 2018
                : 29 August 2018
                Funding
                Funded by: Innovative Medicines Initiative Joint Undertaking
                Award ID: 115523 | 115620 | 115737
                Categories
                Research
                Custom metadata
                © The Author(s) 2018

                Infectious disease & Microbiology
                multidrug-resistance,complicated urinary tract infection,gram-negative bacteria,predictive model of multidrug-resistance gram-negative bacteria

                Comments

                Comment on this article